Cited by 642

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Single-cell landscape of immunological responses in patients with COVID-19

Zhang, Ji-Yuan, Wang, Xiang-Ming, Xing, Xudong, Xu, Zhe, Zhang, Chao, Song, Jin-Wen, Fan, Xing, Xia, Peng, Fu, Jun-Liang, Wang, Si-Yu, Xu, Ruo-Nan, Dai, Xiao-Peng, Shi, Lei, Huang, Lei, Jiang, Tian-Jun, Shi, Ming, Zhang, Yuxia, Zumla, Alimuddin, Maeurer, Markus, Bai, Fan, Wang, Fu-Sheng·2020·Nature Immunology

Published version of a preprint

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41590-020-0762-x

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 37

  1. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 5, 536–544 (2020). · DOI
  2. Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271–280 (2020). · DOI · Paper page
  3. Hoehl, S. et al. Evidence of SARS-CoV-2 infection in returning travelers from Wuhan, China. N. Engl. J. Med. 382, 1278–1280 (2020). · DOI
  4. Rothe, C. et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N. Engl. J. Med. 382, 970–971 (2020). · DOI
  5. He, X. et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat. Med. 26, 672–675 (2020). · DOI
  6. Zou, L. et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N. Engl. J. Med. 382, 1177–1179 (2020). · DOI
  7. Pan, Y., Zhang, D., Yang, P., Poon, L. L. & Wang, Q. Viral load of SARS-CoV-2 in clinical samples. Lancet Infect. Dis. 20, 411–412 (2020). · DOI · Paper page
  8. Peiris, J. S. M. et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 361, 1767–1772 (2003). · DOI · Paper page
  9. Cao, X. COVID-19: immunopathology and its implications for therapy. Nat. Rev. Immunol. 20, 269–270 (2020). · DOI · Paper page
  10. Wang, D. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323, 1061–1069 (2020). · DOI · Paper page
  11. Zhang, C., Shi, L. & Wang, F.-S. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol. Hepatol. 5, 428–430 (2020). · DOI
  12. Chen, N. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395, 507–513 (2020). · DOI · Paper page
  13. Thevarajan, I. et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat. Med. 26, 453–455 (2020). · DOI
  14. Chen, G. et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Invest. 130, 2620–2629 (2020). · DOI · Paper page
  15. Tan, L. et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct. Target Ther. 5, 33 (2020). · DOI
  16. Liao, M. et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat. Med. 26, 842–844 (2020). · DOI · Paper page
  17. Zheng, H. Y. et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell Mol. Immunol. 17, 541–543 (2020). · DOI · Paper page
  18. Qin, C. et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin. Infect. Dis. 71, 762–768 (2020). · DOI · Paper page
  19. Okba, N. M. A. et al. Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease 2019 patients. Emerg. Infect. Dis. 26, 1478–1488 (2020). · DOI · Paper page
  20. Xiang, F. et al. Antibody detection and dynamic characteristics in patients with COVID-19. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciaa461 (2020). · DOI
  21. Iwasaki, A. & Yang, Y. The potential danger of suboptimal antibody responses in COVID-19. Nat. Rev. Immunol. 20, 339–341 (2020). · DOI
  22. Wang, F. S. & Zhang, C. What to do next to control the 2019-nCoV epidemic? Lancet 395, 391–393 (2020). · DOI
  23. Zheng, C. et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell 169, 1342–1356 (2017). · DOI · Paper page
  24. Fu, J. et al. Impairment of CD4+ cytotoxic T cells predicts poor survival and high recurrence rates in patients with hepatocellular carcinoma. Hepatology 58, 139–149 (2013). · DOI
  25. Raveney, B. J. et al. Eomesodermin-expressing T-helper cells are essential for chronic neuroinflammation. Nat. Commun. 6, 8437 (2015). · DOI
  26. Brown, D. M. Cytolytic CD4 cells: direct mediators in infectious disease and malignancy. Cell Immunol. 262, 89–95 (2010). · DOI
  27. Pizzolato, G. et al. Single-cell RNA sequencing unveils the shared and the distinct cytotoxic hallmarks of human TCRVδ1 and TCRVδ2 γδ T lymphocytes. Proc. Natl Acad. Sci. USA 116, 11906–11915 (2019). · DOI
  28. Couzi, L. et al. Common features of γδ T cells and CD8+ αβ T cells responding to human cytomegalovirus infection in kidney transplant recipients. J. Infect. Dis. 200, 1415–1424 (2009). · DOI
  29. Déchanet, J. et al. Implication of γδ T cells in the human immune response to cytomegalovirus. J. Clin. Invest. 103, 1437–1449 (1999). · DOI
  30. Farnault, L. et al. Clinical evidence implicating γδ T cells in EBV control following cord blood transplantation. Bone Marrow Transpl. 48, 1478–1479 (2013). · DOI
  31. Fujishima, N. et al. Skewed T cell receptor repertoire of Vδ1+ γδ T lymphocytes after human allogeneic haematopoietic stem cell transplantation and the potential role for Epstein–Barr virus-infected B cells in clonal restriction. Clin. Exp. Immunol. 149, 70–79 (2007). · DOI
  32. Maeurer, M. et al. Human intestinal Vδ1+ lymphocytes recognize tumor cells of epithelial origin. J. Exp. Med. 183, 1681–1696 (1996). · DOI
  33. Chu, H. et al. Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciaa410 (2020). · DOI
  34. O’Brien, T. R. et al. Weak induction of interferon expression by severe acute respiratory syndrome coronavirus 2 supports clinical trials of interferon-λ to treat early COVID-19. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciaa453 (2020). · DOI
  35. Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888–1902 (2019). · DOI · Paper page
  36. Venteicher, A. S. et al. Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. Science 355, eaai8478 (2017). · DOI
  37. Puram, S. V. et al. Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer. Cell 171, 1611–1624 (2017). · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Zhang, J.-Y., Wang, X.-M., Xing, X., Xu, Z., Zhang, C., Song, J.-W., Fan, X., Xia, P., Fu, J.-L., Wang, S.-Y., Xu, R.-N., Dai, X.-P., Shi, L., Huang, L., Jiang, T.-J., Shi, M., Zhang, Y., Zumla, A., Maeurer, M., Bai, F., & Wang, F.-S.
Venue
Nature Immunology
Published
2020-08-12
Volume
21
Issue
9
Pages
1107-1118
ISSN
  • 1529-2908
  • 1529-2916
Cited by
642
References
10
Language
en
Funders
Ministry of Science and Technology of the People’s Republic of China (2020YFC0841900, 2020YFC0844000)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review